T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022
T2 Biosystems, Inc. (NASDAQ: TTOO) announced it will report its financial results for Q4 and FY 2021 on February 17, 2022, after market close. The company will host a conference call at 4:30 p.m. ET that day, providing details on its financial performance and developments in its product pipeline, including rapid detection technologies for sepsis-causing pathogens. Investors can access the call via a live webcast or by phone.
- T2 Biosystems is a leader in rapid detection technologies, which could benefit future revenue growth.
- The company has an active pipeline with multiple products aimed at detecting various pathogens, indicating potential for innovation and market expansion.
- The timing of the financial results announcement may indicate ongoing challenges or delays in key areas of the business.
LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International) five to ten minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com
415-937-5406
FAQ
When will T2 Biosystems report its financial results?
What will T2 Biosystems discuss in its conference call?
How can I access T2 Biosystems' conference call?
What is T2 Biosystems' stock symbol?
